Published in Oncol Lett on July 26, 2012
Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol (2015) 0.78
Combined detection of liver stiffness and C-reactive protein in patients with hepatitis B virus-related liver cirrhosis, with and without hepatocellular carcinoma. Mol Clin Oncol (2016) 0.75
Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med (2011) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Obesity and hepatocellular carcinoma. Gastroenterology (2004) 2.38
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology (2004) 2.08
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut (2011) 1.98
Improved survival with screening for hepatocellular carcinoma. Liver Transpl (2000) 1.37
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood (2002) 1.32
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol (2006) 1.29
Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci (2007) 1.24
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Enhanced detection of hepatocellular carcinoma. Cancer Control (2005) 1.05
Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol (1999) 1.05
Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol (2003) 0.96
Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci (2010) 0.93
Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst (2007) 0.89
Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am (2000) 0.82
Interleukin-2 signaling and inherited immunodeficiency. Am J Hum Genet (1999) 0.82
Current status of alpha-fetoprotein testing. Gastroenterol Hepatol (N Y) (2011) 0.80
The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science (2007) 11.15
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet (2007) 6.11
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J (2002) 4.83
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
The Ectocarpus genome and the independent evolution of multicellularity in brown algae. Nature (2010) 3.60
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Genetic drift at expanding frontiers promotes gene segregation. Proc Natl Acad Sci U S A (2007) 3.14
The Selaginella genome identifies genetic changes associated with the evolution of vascular plants. Science (2011) 3.10
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol (2007) 3.08
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
Orientation discrimination of single-stranded DNA inside the alpha-hemolysin membrane channel. Proc Natl Acad Sci U S A (2005) 3.06
Toward defining the autoimmune microbiome for type 1 diabetes. ISME J (2010) 3.03
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
The African coelacanth genome provides insights into tetrapod evolution. Nature (2013) 2.78
The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes (2008) 2.77
Virus shapes and buckling transitions in spherical shells. Phys Rev E Stat Nonlin Soft Matter Phys (2003) 2.74
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes (2005) 2.63
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Genomic analysis of detoxification genes in the mosquito Aedes aegypti. Insect Biochem Mol Biol (2007) 2.38
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35
The genome of Nectria haematococca: contribution of supernumerary chromosomes to gene expansion. PLoS Genet (2009) 2.29
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol (2007) 2.23
Direct visualization of dislocation dynamics in grain-boundary scars. Nat Mater (2005) 2.22
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 2.21
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Gene surfing in expanding populations. Theor Popul Biol (2007) 2.19
Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One (2011) 2.18
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12
Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol (2004) 2.09
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
DNA unzipped under a constant force exhibits multiple metastable intermediates. Proc Natl Acad Sci U S A (2003) 2.06
Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med (2011) 2.04
In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes (2004) 2.01
Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab (2012) 2.01
B cells enhance early innate immune responses during bacterial sepsis. J Exp Med (2011) 1.99
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 1.99
Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril (2002) 1.97
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Foldable structures and the natural design of pollen grains. Proc Natl Acad Sci U S A (2010) 1.97
Single molecule statistics and the polynucleotide unzipping transition. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.94
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Identification of liver cancer-specific aptamers using whole live cells. Anal Chem (2008) 1.90
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 1.88
Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol (2006) 1.86
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest (2012) 1.84
Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes. Diabetes Care (2004) 1.81
C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet (2002) 1.80
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Sexual dysfunction in men undergoing infertility evaluation: a cohort observational study. Fertil Steril (2003) 1.76
Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75
Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J (2009) 1.74
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2011) 1.72
Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol (2008) 1.72
Why can't we prevent type 1 diabetes?: maybe it's time to try a different combination. Diabetes Care (2003) 1.71
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.70
Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One (2010) 1.70
Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev (2012) 1.68
Influence of fecal sample storage on bacterial community diversity. Open Microbiol J (2009) 1.68
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril (2003) 1.66